KLF3 and breast carcinoma: As indicated in Figure 10, the expression of KLF3 was downregulated in stage I-IV, metastatic vs. nonmetastatic groups, in every molecular subtype (luminal A, luminal B, and triple negative), and in patients that were either on treatment or naïve to any kind of breast cancer treatment as compared to healthy controls.